Intestinal enteroendocrine L cells, responsive for secreting glucagon-like peptide-1 (GLP-1) to normalize blood glucose level, are negatively affected when type 2 diabetes (T2D) develops. Here, we designed enhanced artificial “intestinal enteroendocrine L cells” (EcN-GLP-1@Fe-TA-Pe@CLGN) for T2D treatment via oral administration.